Innovation1 Biotech Inc
Innovation1 Biotech Inc. focuses on researching, developing, producing, and selling pharmaceutical products. The company offers natural supplements for the treatment of symptoms associated with the flu and long covid under the NutraFlu and Nutravid19 brands; and other supplement and medical nutrition products. It also develops NLC001 that is in Phase II clinical trial for the treatment of long co… Read more
Innovation1 Biotech Inc (IVBT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of February 2024: 0.044x
Based on the latest financial reports, Innovation1 Biotech Inc (IVBT) has a cash flow conversion efficiency ratio of 0.044x as of February 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-148.29K) by net assets ($-3.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Innovation1 Biotech Inc - Cash Flow Conversion Efficiency Trend (2018–2023)
This chart illustrates how Innovation1 Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Innovation1 Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innovation1 Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hempacco Co., Inc.
PINK:HPCO
|
1.121x |
|
INNODIS LTD
SEM:HWF
|
N/A |
|
Aartech Solonics Limited
NSE:AARTECH
|
0.046x |
|
Lecico Egypt
EGX:LCSW
|
N/A |
|
Optima Medical Innovations Corp
PINK:TOKIF
|
0.013x |
|
Evolution Global Acquisition Corp Warrants
NASDAQ:EVOXW
|
N/A |
|
TJIWI KIMIA
MU:OB9
|
N/A |
|
PT Merdeka Gold Resources Tbk
JK:EMAS
|
N/A |
Annual Cash Flow Conversion Efficiency for Innovation1 Biotech Inc (2018–2023)
The table below shows the annual cash flow conversion efficiency of Innovation1 Biotech Inc from 2018 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-08-31 | $-3.43 Million | $-620.20K | 0.181x | +116.49% |
| 2022-08-31 | $2.85 Million | $-3.13 Million | -1.097x | -910.84% |
| 2021-08-31 | $-224.84K | $-30.41K | 0.135x | -11.72% |
| 2020-08-31 | $-2.68 Million | $-410.25K | 0.153x | +100.64% |
| 2019-08-31 | $32.36K | $-775.93K | -23.977x | -852.87% |
| 2018-08-31 | $175.88K | $-442.56K | -2.516x | -- |